BMRN logo

BMRN BioMarin Pharmaceutical Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$60.41
-1.01 (-1.64%)

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disor…

Market Cap: $11.70Bwww.biomarin.com

Price

No data yet.

Social Signal Score

50
5d
50
3 mentions
—
30d
49
16 mentions
—
60d
50
22 mentions
—
90d
50
41 mentions
—
news: 29 · rss: 9 · marketaux: 3

Analyst Ratings

41 analysts
Buyconsensus
Strong Buy 0Buy 29Hold 12Sell 0Strong Sell 0
Avg price target$92.36+52.9%
Low $59Median $92High $122
Current Consensus

Revenue

$1.02B+241.45%
$300.09M$541.61M$783.13M$1.02B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$2.21
$2.06–$2.57
12 analysts
FY2026
$3.00+36% YoY
$2.78–$3.68
17 analysts
FY2027
$6.34+111% YoY
$4.10–$7.24
17 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Alexander Hardy
Sector
Healthcare
Industry
Biotechnology
Employees
3,221
Beta
0.21
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
1.95
www.biomarin.com